KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Current Deferred Revenue (2018 - 2020)

Historic Current Deferred Revenue for Astrazeneca (AZN) over the last 3 years, with Q4 2020 value amounting to $12.0 million.

  • Astrazeneca's Current Deferred Revenue fell 5714.29% to $12.0 million in Q4 2020 from the same period last year, while for Dec 2020 it was $12.0 million, marking a year-over-year decrease of 5714.29%. This contributed to the annual value of $12.0 million for FY2020, which is 5714.29% down from last year.
  • Astrazeneca's Current Deferred Revenue amounted to $12.0 million in Q4 2020, which was down 5714.29% from $28.0 million recorded in Q4 2019.
  • In the past 5 years, Astrazeneca's Current Deferred Revenue ranged from a high of $92.0 million in Q4 2018 and a low of $12.0 million during Q4 2020
  • Over the past 3 years, Astrazeneca's median Current Deferred Revenue value was $28.0 million (recorded in 2019), while the average stood at $44.0 million.
  • Per our database at Business Quant, Astrazeneca's Current Deferred Revenue plummeted by 6956.52% in 2019 and then plummeted by 5714.29% in 2020.
  • Over the past 3 years, Astrazeneca's Current Deferred Revenue (Quarter) stood at $92.0 million in 2018, then tumbled by 69.57% to $28.0 million in 2019, then plummeted by 57.14% to $12.0 million in 2020.
  • Its Current Deferred Revenue stands at $12.0 million for Q4 2020, versus $28.0 million for Q4 2019 and $92.0 million for Q4 2018.